Lv7
4735 积分 2020-03-31 加入
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial
25天前
已完结
Tirabrutinib: First Approval
1个月前
已完结
Efficacy and safety of orelabrutinib combined with rituximab and high dose methotrexate in primary or secondary central nervous system diffuse large B-cell lymphoma: a retrospective analysis
1个月前
已完结
Circulating tumor DNA from blood and cerebrospinal fluid in DLBCL: simultaneous evaluation of mutations, IG rearrangement, and IG clonality
1个月前
已完结
Anti-CD19 antibody tafasitamab therapy for relapsed or refractory diffuse large B-cell lymphoma: a case series
1个月前
已完结
The emerging role of tafasitamab in follicular lymphoma
2个月前
已关闭
Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience
3个月前
已完结
Treatment strategies for patients with diffuse large B-cell lymphoma
3个月前
已完结
Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis
3个月前
已完结
Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances
4个月前
已完结
皖公网安备34019202002308
